Ezetimibe/Rosuvastatin Calcium/Valsartan

依折麦布/瑞舒伐他汀钙/缬沙坦

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEzetimibe/Rosuvastatin Calcium/Valsartan
Drug Alias NameLGEV-1801+LGEV-1802缬沙坦+依折麦布+瑞舒伐他汀Valsartan+Ezetimibe+RosuvastatinEV-81
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsHMG-CoA reductase inhibitorsNiemann-Pick C1-like protein 1 inhibitors +[4] 
TargetsAngiotensin II Receptor Type 1HMG-CoA reductaseNiemann-Pick C1-like protein 1
Therapy Area/IndicationsDyslipidemiasHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes ValsartanEzetimibeRosuvastatin Calcium
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLg Chemical Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLg Chemical Ltd
Inactive CompaniesN/A
Active IndicationsDyslipidemiasHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A